Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Macular Degeneration

Judi Dench admits she cannot see on film sets due to vision loss

The Oscar-winning actress previously revealed she has macular degeneration, which causes the gradual loss of vision.

Evening Standard

People over State Pension age with poor eyesight could be due up to £101 each week

Attendance Allowance could help people with cataract, glaucoma or macular degeneration.

Daily Record

People over State Pension age with eyesight issues could be due up to £407 each month

Attendance Allowance could help if you have an eye condition such as cataract, glaucoma or macular degeneration.

Daily Record

From analysis to the latest developments in health,
read the most diverse news in one place.

People over State Pension age with eyesight issues could be due up to £407 each month

Attendance Allowance could help if you have an eye condition such as cataract, glaucoma or macular degeneration.

Daily Record

Dry eyes, Myopia and more: 5 reasons you're getting these eye problems

The prevalence of non-communicable eye diseases is rising worldwide, especially in India. According to the findings of several worldwide research, Indians have a greater chance of developing diabetes and glaucoma-related vision issues, including total blindness. It is essential that eye disorders are identified early and the appropriate preventative measures are…

The Times of India

Judi Dench, 88, reveals she's now completely unable to read scripts due to illness

Having first revealed her diagnosis in 2012, James Bond star Judi Dench has admitted that her advanced macular degeneration is really impacting her ability to be independent

Daily Mirror

Dame Judi Dench can no longer read scripts because of failing eyesight

Wales Online

Read news from The Economist, FT, and more,
with one subscription

Macular diseases cause blindness and treatment costs millions. Here is how to look after yours

The single most expensive drug for the Australian government today, costing more than A$400 million per year, is one called aflibercept. It stops the growth and “leakiness” of blood vessels, and is given to treat a range of different eye diseases. These diseases have one thing in common: they all…

The Conversation

When blindness is a clue to bigger problems

People with a specific form of age-related macular degeneration are also highly likely to have either underlying heart damage.

The New Daily

Age-related macular degeneration (AMD) signs after Dame Judi Dench's admission

The condition has severely impacted the actress' vision and career

Liverpool Echo

Poorer eyesight as you get older 'could be an early warning sign of heart disease'

The study's findings provide hope opticians on our high streets could screen for the disease and ultimately prevent cardiac arrests among those affected by the eye condition

Daily Mirror

Health: Blinding Eye Disease Is Linked With Heart Disease And Stroke, Suggests Research

According to a recent study from the New York Eye and Ear Infirmary of Mount Sinai, patients with a particular type of age-related macular degeneration (shoppingmode AMD), the main cause of blindness in the United States. Read on for details:

Dynamite News

What is macular degeneration? Judi Dench's eye condition stops her reading scripts

Oscar winner Dame Judi Dench cannot read scripts anymore due to the eye condition know as macular degeneration. Here is a guide for how to best spot the symptoms, and why regular eye tests are so important

Daily Mirror

Judi Dench refuses to quit acting despite struggling to read or write due to macular degeneration

The legendary actress has an advanced stage of the condition, which impairs vision

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

The New Daily

New supplement works better at slowing macular degeneration

New research shows that the much safer AREDS2 supplement works better at slowing the progress of age-related macular degeneration.

Benzinga

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Get all your
news in one place.

100's of premium titles.
One news app.

Zenger

Scientists Discover Genetic Clues That Can Lead To Better Treatment For Blindness-Causing Conditions

Better treatments for an eye condition that can cause blindness are a major step closer after scientists discovered genetic clues that show who has it.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Adverum Biotech Receives EMA's Priority Medicines Status For Chronic Eye Disorder Candidate

The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ (NASDAQ: ADVM) lead drug ADVM-022 for the treatment of wet age-related macular degeneration (wet AMD).

Benzinga

Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy

Adverum Biotechnologies Inc (NASDAQ:ADVM) has shared new data from the ADVM-022 development program in wet age-related macular degeneration (wet AMD). The data were presented at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting. It exhibited results of the non-human primate (NHP) studies that provide support for the new 6…

Benzinga

Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data. 89% (319/359) of patients…

Benzinga

BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT

Benzinga

Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study

Stealth BioTherapeutics Corp (NASDAQ:MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degeneration. Although the trial did not meet its primary endpoints, a key secondary endpoint showed that elamipretide categorically improved visual function for patients with GA. The study did…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.